RELMADA THERAPEUTICS, INC.: 10-Q filed 2021-05-12
What RELMADA THERAPEUTICS, INC. reported in its quarterly report filed 2021-05-12 (fiscal Q1 2021): 28 published measures, 59 facts as tagged in accession 0001213900-21-025786.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2021-05-12
- Fiscal period
- fiscal Q1 2021
- Accession
- 0001213900-21-025786 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All RELMADA THERAPEUTICS, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-03-31 | 103,866,508 | USD | |
| At 2020-12-31 | 118,186,204 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-03-31 | 91,147,128 | USD | |
| At 2020-12-31 | 105,582,746 | USD | |
| At 2020-03-31 | 113,159,533 | USD | |
| At 2019-12-31 | 115,678,294 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-03-31 | 3,804,042 | USD | |
| At 2020-12-31 | 2,495,397 | USD | |
| At 2020-03-31 | 12,226,487 | USD | |
| At 2019-12-31 | 36,278,519 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-03-31 | -22,215,181 | USD | 90 |
| 2020-01-01 to 2020-03-31 | -10,673,316 | USD | 91 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-03-31 | -16,085,475 | USD | 90 |
| 2020-01-01 to 2020-03-31 | -3,424,763 | USD | 91 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-03-31 | 1,928,279 | USD | 90 |
| 2020-01-01 to 2020-03-31 | 3,004,946 | USD | 91 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-03-31 | 15,465,841 | USD | 90 |
| 2020-01-01 to 2020-03-31 | -23,632,215 | USD | 91 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-03-31 | -201,530,484 | USD | |
| At 2020-12-31 | -179,315,303 | USD |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-03-31 | 452 | USD | |
| At 2020-12-31 | 1,258 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-03-31 | 5,851,284 | USD | 90 |
| 2020-01-01 to 2020-03-31 | 5,039,362 | USD | 91 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-03-31 | -22,405,203 | USD | 90 |
| 2020-01-01 to 2020-03-31 | -9,974,438 | USD | 91 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-03-31 | 103,775,602 | USD | |
| At 2020-12-31 | 118,073,569 | USD |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-03-31 | 12,719,380 | USD | |
| At 2020-12-31 | 12,603,458 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-03-31 | 8,082,796 | USD | |
| At 2020-12-31 | 8,346,475 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-03-31 | 22,405,203 | USD | 90 |
| 2020-01-01 to 2020-03-31 | 9,974,438 | USD | 91 |
Research and development expense
Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-03-31 | 14,022,227 | USD | 90 |
| 2020-01-01 to 2020-03-31 | 4,507,784 | USD | 91 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-03-31 | 16,748,055 | shares | |
| At 2020-12-31 | 16,332,939 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-03-31 | 292,660,864 | USD | |
| At 2020-12-31 | 284,881,716 | USD |
Gross property, plant and equipment
Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-03-31 | 16,700 | USD | |
| At 2020-12-31 | 16,700 | USD |
Accumulated depreciation on property, plant and equipment
Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-03-31 | 16,200 | USD | |
| At 2020-12-31 | 15,400 | USD |
Other noncurrent assets
Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-03-31 | 25,000 | USD | |
| At 2020-12-31 | 25,000 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2021-03-31 | 4,636,584 | USD | |
| At 2020-12-31 | 4,256,983 | USD |
Profit or loss including noncontrolling interests
Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-03-31 | -22,215,181 | USD | 90 |
| 2020-01-01 to 2020-03-31 | -10,673,316 | USD | 91 |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-03-31 | 8,382,976 | USD | 90 |
| 2020-01-01 to 2020-03-31 | 5,466,654 | USD | 91 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-03-31 | 806 | USD | 90 |
| 2020-01-01 to 2020-03-31 | 1,046 | USD | 91 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-03-31 | 190,022 | USD | 90 |
| 2020-01-01 to 2020-03-31 | -698,878 | USD | 91 |
Interest paid, net
Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-03-31 | 2,415 | USD | 91 |
Change in accounts payable
The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2021-01-01 to 2021-03-31 | -263,679 | USD | 90 |
| 2020-01-01 to 2020-03-31 | 580,153 | USD | 91 |
Inspect the source
- Entity
- RELMADA THERAPEUTICS, INC. / CIK 0001553643
- Captured
- 2026-09-19T11:18:56.464Z
- SEC response SHA-256
34acb6579adb694402af1f940d83014f7841c8cf763b03e27ee64d386466bb53
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001553643.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))